Literature DB >> 21633818

A proposed model for economic evaluations of major depressive disorder.

Hossein Haji Ali Afzali1, Jonathan Karnon, Jodi Gray.   

Abstract

In countries like UK and Australia, the comparability of model-based analyses is an essential aspect of reimbursement decisions for new pharmaceuticals, medical services and technologies. Within disease areas, the use of models with alternative structures, type of modelling techniques and/or data sources for common parameters reduces the comparability of evaluations of alternative technologies for the same condition. The aim of this paper is to propose a decision analytic model to evaluate long-term costs and benefits of alternative management options in patients with depression. The structure of the proposed model is based on the natural history of depression and includes clinical events that are important from both clinical and economic perspectives. Considering its greater flexibility with respect to handling time, discrete event simulation (DES) is an appropriate simulation platform for modelling studies of depression. We argue that the proposed model can be used as a reference model in model-based studies of depression improving the quality and comparability of studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21633818     DOI: 10.1007/s10198-011-0321-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  59 in total

1.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

Review 2.  Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.

Authors:  Sheikh Usman Iqbal; Mark Prashker
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Health economic evaluations of antidepressants: a review.

Authors:  T R Hylan; D P Buesching; G D Tollefson
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

4.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

Review 5.  A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

6.  A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Patrick W Sullivan; Robert Valuck; Joseph Saseen; Holly M MacFall
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Prediction of the three-year course of recurrent depression in primary care patients: different risk factors for different outcomes.

Authors:  Henk Jan Conradi; Peter de Jonge; Johan Ormel
Journal:  J Affect Disord       Date:  2007-06-14       Impact factor: 4.839

8.  Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.

Authors:  Agnes Benedict; Jorge Arellano; Erwin De Cock; Jessamy Baird
Journal:  J Affect Disord       Date:  2010-01       Impact factor: 4.839

9.  Long-term outcome of episodes of major depression. Clinical and public health significance.

Authors:  M B Keller; G L Klerman; P W Lavori; W Coryell; J Endicott; J Taylor
Journal:  JAMA       Date:  1984-08-10       Impact factor: 56.272

Review 10.  The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm.

Authors:  Helen Campbell; Andrew Briggs; Martin Buxton; Lois Kim; Simon Thompson
Journal:  J Health Serv Res Policy       Date:  2007-01
View more
  6 in total

Review 1.  Exploring structural uncertainty in model-based economic evaluations.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 2.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 3.  A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Evaluation of collaborative models of care in the management of patients with depression: protocol and progress.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray; Justin Beilby
Journal:  Ment Health Fam Med       Date:  2012-06

5.  Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis.

Authors:  Jodi Gray; Hossein Haji Ali Afzali; Justin Beilby; Christine Holton; David Banham; Jonathan Karnon
Journal:  BMC Fam Pract       Date:  2014-01-14       Impact factor: 2.497

6.  Cost-Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation.

Authors:  Mathias Baumann; Tom Stargardt; Simon Frey
Journal:  Appl Health Econ Health Policy       Date:  2020-08       Impact factor: 2.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.